BCR-ABL融合基因和JAK2 V617F基因突变双阳性骨髓增殖性肿瘤的研究进展  

Progress of BCR-ABL fusion gene and JAK2 V617F mutation double-positive myeloproliferative neoplasms

作　　者：邢明泉 葛洪峰[1] 吴维霞 孙晓星[1] 马兰[3] 王其凯 韩浩 Xing Mingquan;Ge Hongfeng;Wu Weixia;Sun Xiaoxing;Ma Lan;Wang Qikai;Han Hao(Department of Hematology,Bozhou People's Hospital,Bozhou 236800,China;Image Center,Bozhou People's Hospital,Bozhou 236800,China;Department of Infectious Medicine,Bozhou People's Hospital,Bozhou 236800,China)

机构地区：[1]亳州市人民医院血液内科,亳州236800 [2]亳州市人民医院影像中心,亳州236800 [3]亳州市人民医院感染内科,亳州236800

出　　处：《白血病．淋巴瘤》2022年第10期637-640,共4页Journal of Leukemia & Lymphoma

摘　　要：骨髓增殖性肿瘤(MPN)是一组造血干细胞克隆性疾病,JAK2V 617F基因突变为MPN诊断的主要依据。既往研究显示MPN患者BCR-ABL融合基因与JAK2 V617F基因突变是互相排斥的,但近年来两种基因双突变病例时有报道。文章综合近年来国内外相关文献,对BCR-ABL融合基因与JAK2 V617F突变双阳性的MPN进行综述。Myeloproliferative neoplasms (MPN) are a group of clonal disorders of hematopoietic stem cells, and JAK2 V617F gene mutation is the main basis for the diagnosis of MPN. Previous studies have shown that BCR-ABL fusion gene and JAK2 V617F gene mutation are mutually exclusive in MPN patients, but in recent years, patients with a double mutation of both genes are often reported. The article synthesizes the relevant domestic and foreign literature in recent years, and reviews the BCR-ABL fusion gene and JAK2 V617F mutation double-positive MPN.

关 键 词：骨髓增殖性肿瘤 BCR-ABL融合基因JAK2 V617F基因突变 

分 类 号：R733.3[医药卫生—肿瘤]